Brief: Immunicum: Encouraging Signs Of Survival Benefit In Phase II MERECA Trial Of Ilixadencel In Kidney Cancer
22/02/2021 07:07
Feb 22 (Reuters) - Immunicum AB IMMUN.ST :
* REG-IMMUNICUM ANNOUNCES ENCOURAGING SIGNS OF SURVIVAL
BENEFIT IN
PHASE II MERECA TRIAL OF ILIXADENCEL IN KIDNEY CANCER
* MEDIAN OVERALL SURVIVAL (OS) FOR ILIXADENCEL COMBINATION
TREATMENT GROUP HAS BEEN REACHED AT 35.6 MONTHS, AS COMPARED TO
25.3 MONTHS FOR SUNITINIB CONTROL GROUP
* RESULTS INDICATE POTENTIAL SURVIVAL BENEFIT FOR PATIENTS
IN
ILIXADENCEL COMBINATION GROUP
Source text for Eikon: ID:nGNEJr2yL
Further company coverage: IMMUN.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587696600;))